PMID

Data

Article Title

Organization

Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.

University of Melbourne

Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.

University of Melbourne

2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition.

University of Melbourne

Minimization of human relaxin-3 leading to high-affinity analogues with increased selectivity for relaxin-family peptide 3 receptor (RXFP3) over RXFP1.

University of Melbourne

Irreversible inhibition of dihydrodipicolinate synthase by 4-oxo-heptenedioic acid analogues.

University of Melbourne

Aryl sulfamates are broad spectrum inactivators of sulfatases: effects on sulfatases from various sources.

University of Melbourne

Conformationally constrained diketopimelic acid analogues as inhibitors of dihydrodipicolinate synthase.

University of Melbourne

Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.

University of Melbourne

Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.

University of Melbourne

Effects of C-Terminal B-Chain Modifications in a Relaxin 3 Agonist Analogue.

University of Melbourne

Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.

University of Melbourne

Human Insulin-like Peptide 5 (INSL5). Identification of a Simplified Version of Two-Chain Analog A13.

University of Melbourne

Structure-Activity Relationships of

University of Melbourne

Exploration of the P3 region of PEXEL peptidomimetics leads to a potent inhibitor of the Plasmodium protease, plasmepsin V.

University of Melbourne

Challenges in the design of insulin and relaxin/insulin-like peptide mimetics.

University of Melbourne

ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF

University Of California

2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors

4Sc

Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia (dagger) dagger Coordinates of the PDE10A crystal structures have been depo

Pfizer